dc.contributor.author |
Díaz-Beyá, Marina |
dc.contributor.author |
Brunet, Salut |
dc.contributor.author |
Nomdedeu, Josep |
dc.contributor.author |
Cordeiro, A. |
dc.contributor.author |
Tormo, M. |
dc.contributor.author |
Escoda, Lourdes |
dc.contributor.author |
Ribera, Jose-Maria |
dc.contributor.author |
Arnan, Montserrat |
dc.contributor.author |
Heras, Inmaculada |
dc.contributor.author |
Gallardo, David |
dc.contributor.author |
Bargay, Joan |
dc.contributor.author |
Queipo de Llano, M. P. |
dc.contributor.author |
Salamero, Olga |
dc.contributor.author |
Martí, J. M. |
dc.contributor.author |
Sampol, Antonia |
dc.contributor.author |
Pedro, Carme |
dc.contributor.author |
Hoyos Colell, Montserrat |
dc.contributor.author |
Pratcorona, M. |
dc.contributor.author |
Castellano, J. J. |
dc.contributor.author |
Nomdedeu, Meritxell |
dc.contributor.author |
Risueño, Ruth M |
dc.contributor.author |
Sierra, J. |
dc.contributor.author |
Monzó, Mariano |
dc.contributor.author |
Navarro Ponz, Alfons |
dc.contributor.author |
Esteve Reyner, Jordi |
dc.contributor.author |
Universitat Autònoma de Barcelona |
dc.date |
2015 |
dc.identifier |
https://ddd.uab.cat/record/185437 |
dc.identifier |
urn:10.1038/bcj.2015.76 |
dc.identifier |
urn:oai:ddd.uab.cat:185437 |
dc.identifier |
urn:oai:egreta.uab.cat:publications/33b0c3b1-a02a-4ac8-bb45-0ed70500bf59 |
dc.identifier |
urn:pmid:26430723 |
dc.identifier |
urn:scopus_id:84943169416 |
dc.identifier |
urn:articleid:20445385v5e352 |
dc.identifier |
urn:pmc-uid:4635188 |
dc.identifier |
urn:pmcid:PMC4635188 |
dc.identifier |
urn:oai:pubmedcentral.nih.gov:4635188 |
dc.format |
application/pdf |
dc.language |
eng |
dc.publisher |
|
dc.relation |
Agència de Gestió d'Ajuts Universitaris i de Recerca 2014SGR-1281 |
dc.relation |
Instituto de Salud Carlos III PI13-00999 |
dc.relation |
Blood Cancer Journal ; Vol. 5 (october 2015), p. e352 |
dc.rights |
open access |
dc.rights |
Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original. |
dc.rights |
https://creativecommons.org/licenses/by/4.0/ |
dc.title |
The expression level of BAALC -associated microRNA miR-3151 is an independent prognostic factor in younger patients with cytogenetic intermediate-risk acute myeloid leukemia |
dc.type |
Article |
dc.description.abstract |
Acute myeloid leukemia (AML) is a heterogeneous disease whose prognosis is mainly related to the biological risk conferred by cytogenetics and molecular profiling. In elderly patients (⩾60 years) with normal karyotype AML miR-3151 have been identified as a prognostic factor. However, miR-3151 prognostic value has not been examined in younger AML patients. In the present work, we have studied miR-3151 alone and in combination with BAALC, its host gene, in a cohort of 181 younger intermediate-risk AML (IR-AML) patients. Patients with higher expression of miR-3151 had shorter overall survival (P =0.0025), shorter leukemia-free survival (P =0.026) and higher cumulative incidence of relapse (P =0.082). Moreover, in the multivariate analysis miR-3151 emerged as independent prognostic marker in both the overall series and within the unfavorable molecular prognostic category. Interestingly, the combined determination of both miR-3151 and BAALC improved this prognostic stratification, with patients with low levels of both parameters showing a better outcome compared with those patients harboring increased levels of one or both markers (P =0.003). In addition, we studied the microRNA expression profile associated with miR-3151 identifying a six-microRNA signature. In conclusion, the analysis of miR-3151 and BAALC expression may well contribute to an improved prognostic stratification of younger patients with IR-AML. |